FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2238141562> ?p ?o ?g. }

• W2238141562 endingPage "e52" @default.
• W2238141562 startingPage "e45" @default.
• W2238141562 abstract "Graft-versus-host disease (GVHD) is the major limitation of allogeneic haemopoietic stem-cell transplantation (HSCT), for which no approved treatments are available. Use of mesenchymal stromal cells (MSCs) has become standard practice in some European countries, but controversy exists for their benefit. The aim of this meta-analysis was to analyse available evidence for the benefit of MSC treatments in steroid-resistant acute GVHD.We did a systematic review and meta-analysis to assess response to and survival after MSC treatment in patients with steroid-refractory acute GVHD. We searched MEDLINE, Embase, Ovid, and Cochrane Central databases for published studies, and we used ClinicalTrials.gov and other websites to find unpublished studies and conference abstracts. We included prospective and retrospective studies in which MSCs were administered to patients with steroid-refractory acute GVHD. Data were extracted independently by two investigators based on strict selection criteria. A random-effects model was used to pool outcomes across studies because of anticipated heterogeneity. Our primary outcome was survival at 6 months from the first infusion of MSCs.We identified 628 citations with our search, of which 610 were excluded after review and a further five did not contain pertinent data. Thus, our meta-analysis included 13 non-randomised studies at moderate risk of bias, comprising a total of 336 patients. Six studies provided data for the primary outcome analysis (119 patients). Survival at 6 months after MSC treatment was 63% (95% CI 50-74; I(2)=41%). Survival did not differ with respect to age, MSC culture medium, or dose of MSCs delivered.Available evidence suggests that infusion of MSCs could be an acceptable treatment for patients with steroid-refractory acute GVHD. Randomised clinical trials are needed urgently to assess different treatment modalities for steroid-refractory acute GVHD.None." @default.
• W2238141562 created "2016-06-24" @default.
• W2238141562 creator A5003097876 @default.
• W2238141562 creator A5012936889 @default.
• W2238141562 creator A5026575127 @default.
• W2238141562 creator A5035553129 @default.
• W2238141562 creator A5043033429 @default.
• W2238141562 creator A5054802858 @default.
• W2238141562 creator A5069460930 @default.
• W2238141562 creator A5085360755 @default.
• W2238141562 creator A5086329931 @default.
• W2238141562 date "2016-01-01" @default.
• W2238141562 modified "2023-10-16" @default.
• W2238141562 title "Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis" @default.
• W2238141562 cites W1976646672 @default.
• W2238141562 cites W1982408656 @default.
• W2238141562 cites W1982916645 @default.
• W2238141562 cites W1985461212 @default.
• W2238141562 cites W1986142040 @default.
• W2238141562 cites W1988489929 @default.
• W2238141562 cites W1999670686 @default.
• W2238141562 cites W2007536176 @default.
• W2238141562 cites W2012302358 @default.
• W2238141562 cites W2013107151 @default.
• W2238141562 cites W2029833407 @default.
• W2238141562 cites W2033230449 @default.
• W2238141562 cites W2037163385 @default.
• W2238141562 cites W2041864288 @default.
• W2238141562 cites W2042055313 @default.
• W2238141562 cites W2045254759 @default.
• W2238141562 cites W2045979374 @default.
• W2238141562 cites W2056328782 @default.
• W2238141562 cites W2058473775 @default.
• W2238141562 cites W2062388390 @default.
• W2238141562 cites W2079212138 @default.
• W2238141562 cites W2083434602 @default.
• W2238141562 cites W2092929403 @default.
• W2238141562 cites W2094292853 @default.
• W2238141562 cites W2102330961 @default.
• W2238141562 cites W2110752492 @default.
• W2238141562 cites W2111717354 @default.
• W2238141562 cites W2123123013 @default.
• W2238141562 cites W2126021331 @default.
• W2238141562 cites W2129163850 @default.
• W2238141562 cites W2138946470 @default.
• W2238141562 cites W2139656974 @default.
• W2238141562 cites W2141841695 @default.
• W2238141562 cites W2143258371 @default.
• W2238141562 cites W2145512995 @default.
• W2238141562 cites W2160666689 @default.
• W2238141562 cites W2162729702 @default.
• W2238141562 cites W2303816016 @default.
• W2238141562 doi "https://doi.org/10.1016/s2352-3026(15)00224-0" @default.
• W2238141562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26765648" @default.
• W2238141562 hasPublicationYear "2016" @default.
• W2238141562 type Work @default.
• W2238141562 sameAs 2238141562 @default.
• W2238141562 citedByCount "150" @default.
• W2238141562 countsByYear W22381415622016 @default.
• W2238141562 countsByYear W22381415622017 @default.
• W2238141562 countsByYear W22381415622018 @default.
• W2238141562 countsByYear W22381415622019 @default.
• W2238141562 countsByYear W22381415622020 @default.
• W2238141562 countsByYear W22381415622021 @default.
• W2238141562 countsByYear W22381415622022 @default.
• W2238141562 countsByYear W22381415622023 @default.
• W2238141562 crossrefType "journal-article" @default.
• W2238141562 hasAuthorship W2238141562A5003097876 @default.
• W2238141562 hasAuthorship W2238141562A5012936889 @default.
• W2238141562 hasAuthorship W2238141562A5026575127 @default.
• W2238141562 hasAuthorship W2238141562A5035553129 @default.
• W2238141562 hasAuthorship W2238141562A5043033429 @default.
• W2238141562 hasAuthorship W2238141562A5054802858 @default.
• W2238141562 hasAuthorship W2238141562A5069460930 @default.
• W2238141562 hasAuthorship W2238141562A5085360755 @default.
• W2238141562 hasAuthorship W2238141562A5086329931 @default.
• W2238141562 hasConcept C126322002 @default.
• W2238141562 hasConcept C141071460 @default.
• W2238141562 hasConcept C142724271 @default.
• W2238141562 hasConcept C143998085 @default.
• W2238141562 hasConcept C198826908 @default.
• W2238141562 hasConcept C2779972918 @default.
• W2238141562 hasConcept C2911091166 @default.
• W2238141562 hasConcept C535046627 @default.
• W2238141562 hasConcept C71924100 @default.
• W2238141562 hasConcept C95190672 @default.
• W2238141562 hasConceptScore W2238141562C126322002 @default.
• W2238141562 hasConceptScore W2238141562C141071460 @default.
• W2238141562 hasConceptScore W2238141562C142724271 @default.
• W2238141562 hasConceptScore W2238141562C143998085 @default.
• W2238141562 hasConceptScore W2238141562C198826908 @default.
• W2238141562 hasConceptScore W2238141562C2779972918 @default.
• W2238141562 hasConceptScore W2238141562C2911091166 @default.
• W2238141562 hasConceptScore W2238141562C535046627 @default.
• W2238141562 hasConceptScore W2238141562C71924100 @default.
• W2238141562 hasConceptScore W2238141562C95190672 @default.
• W2238141562 hasIssue "1" @default.
• W2238141562 hasLocation W22381415621 @default.

• next